|
業務類別
|
Biotechnology |
|
業務概覽
|
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies. |
| 公司地址
| 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512 |
| 電話號碼
| +1 609 659-8001 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.rocketpharma.com |
| 員工數量
| 202 |
| Ms. Sarbani Chaudhuri, M.B.A. |
Chief Commercial and Medical Affairs Officer |
-- |
06/04/2026 |
| Mr. Christopher Stevens |
Chief Operating Officer |
美元 242.31K |
06/04/2026 |
| Mr. Jonathan Schwartz, M.D. |
Chief Science and Gene Therapy Officer |
-- |
06/04/2026 |
| Dr. Gaurav Shah, M.D. |
Director and Chief Executive Officer |
美元 671.08K |
06/04/2026 |
| Mr. Syed Ali-aamir Rizvi, M.D. |
Chief Medical Officer |
-- |
06/04/2026 |
| Mr. Martin Wilson, J.D. |
General Counsel, Chief Corporate Officer, Senior Vice President and Interim Principal Financial Officer |
美元 488.28K |
06/04/2026 |
| Mr. John Militello, C.P.A. |
Vice President of Finance, Senior Controller, Treasurer and Principal Accounting Officer |
-- |
06/04/2026 |
|
|
| Dr. Mikael Dolsten, M.D.,PhD |
Director |
06/04/2026 |
| Dr. Elisabeth Bjork, M.D.,PhD |
Independent Director |
06/04/2026 |
| Dr. Gaurav Shah, M.D. |
Director and Chief Executive Officer |
06/04/2026 |
| Dr. Fady Ibraham Malik, M.D.,PhD |
Independent Director |
06/04/2026 |
| Dr. Roderick Wong, M.D. |
Chairman of the Board |
06/04/2026 |
| Mr. David P. Southwell |
Independent Director |
06/04/2026 |
| Mr. Carsten Boess |
Independent Director |
06/04/2026 |
| Mr. Piratip Pratumsuwan |
Independent Director |
06/04/2026 |
| Dr. Peter Fong, M.D.,PhD |
Independent Director |
06/04/2026 |
|
|
|
|
